Xbrane Biopharma AB (XBRANE)

Stockholm
Currency in SEK
0.24
-0.01(-4.00%)
Closed·
XBRANE Scorecard
Full Analysis
High shareholder yield
XBRANE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.240.25
52 wk Range
0.130.31
Key Statistics
Edit
Prev. Close
0.25
Open
0.25
Day's Range
0.24-0.25
52 wk Range
0.13-0.31
Volume
12.74M
Average Vol. (3m)
22.36M
1-Year Change
-16.81%
Book Value / Share
0.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XBRANE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.65
Upside
+170.83%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Xbrane Biopharma AB News & Analysis

Show more

Xbrane Biopharma AB Company Profile

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden.

Compare XBRANE to Peers and Sector

Metrics to compare
XBRANE
Peers
Sector
Relationship
P/E Ratio
−2.3x12.4x−0.4x
PEG Ratio
−0.020.480.00
Price / Book
1.7x1.9x2.6x
Price / LTM Sales
1.3x4.7x3.1x
Upside (Analyst Target)
170.8%46.5%51.1%
Fair Value Upside
Unlock14.2%8.9%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.65
(+170.83% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
0.0075 / -0.03
Revenue / Forecast
93.12M / 51.00M
EPS Revisions
Last 90 days

XBRANE Income Statement

FAQ

What Is the Xbrane Biopharma (XBRANE) Stock Price Today?

The Xbrane Biopharma stock price today is 0.24

What Stock Exchange Does Xbrane Biopharma Trade On?

Xbrane Biopharma is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Xbrane Biopharma?

The stock symbol for Xbrane Biopharma is "XBRANE."

What Is the Xbrane Biopharma Market Cap?

As of today, Xbrane Biopharma market cap is 370.79M.

What Is Xbrane Biopharma's Earnings Per Share (TTM)?

The Xbrane Biopharma EPS (TTM) is -0.10.

When Is the Next Xbrane Biopharma Earnings Date?

Xbrane Biopharma will release its next earnings report on Aug 26, 2025.

From a Technical Analysis Perspective, Is XBRANE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Xbrane Biopharma Stock Split?

Xbrane Biopharma has split 2 times.

How Many Employees Does Xbrane Biopharma Have?

Xbrane Biopharma has 64 employees.

What is the current trading status of Xbrane Biopharma (XBRANE)?

As of Jun 15, 2025, Xbrane Biopharma (XBRANE) is trading at a price of 0.24, with a previous close of 0.25. The stock has fluctuated within a day range of 0.24 to 0.25, while its 52-week range spans from 0.13 to 0.31.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.